Description: Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. The company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease. Additional indications for the active ingredient in Trappsol Cyclo are in development.
Home Page: www.cyclotherapeutics.com
CYTH Technical Analysis
6714 NW 16th Street
Gainesville,
FL
32653
United States
Phone:
386 418 8060
Officers
| Name | Title |
|---|---|
| Mr. N. Scott Fine | CEO & Director |
| Mr. C. E Strattan | Founder & Director |
| Mr. Michael Eric Lisjak | Chief Regulatory Officer & Sr. VP of Bus. Devel. |
| Mr. Joshua M. Fine | CFO & Sec. |
| Dr. Jeffrey L. Tate Ph.D. | COO, Chief Quality Officer & Director |
| Mr. George L. Fails | Exec. VP and Operations Mang. |
| Ms. Lori McKenna Gorski | Global Head of Patient Advocacy |
| Dr. Lise Lund Kjems M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8412 |
| Price-to-Sales TTM: | 8.6536 |
| IPO Date: | 2011-02-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |